Sai Life Sciences · risk themes across the available quarters.
Bear-case history
Management explicitly acknowledged they have limited visibility into customer inventory destocking cycles and get impacted when destocking is announced, not before. They can only mitigate through broader portfolio diversification.
Management referenced FY22-23 experience when margin profile dropped post-commercialization of new facility, and warned that front-loaded people investments and operating expenditure ahead of capacity additions could create growth-related challenges affecting margins.
Analyst asked specific questions about GLP-based products in pipeline, clinical stages (Phase 1/2), and whether products are peptide vs non-peptide based. Management deflected, stating they don't comment on specific product pipeline beyond two commercial products, and declined to clarify if 'commercial beyond discovery stage' interpretation was correct.
When asked about split of 7 molecules between primary vs secondary supplier positions, management only confirmed 'probably two of the three' commercial molecules are primary suppliers. Remaining 4 late-phase molecules' supplier status was not clarified.
Input cost inflation and logistics disruptions from geopolitical tensions may not be fully recovered from customers in a timely manner, pressuring margins.
Doubling capex to ₹1,100-1,300 crore could strain organizational capability and lead to inefficiencies, as flagged by an analyst question on execution fragility.
Revenue from new modalities fell from 7% to 4% of total, indicating lumpiness in clinical-stage campaigns and potential competitive pressure.
Top 10 customers contribute 54% of revenue; loss of any key customer could materially impact results.